Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trialMaria Domenica Cappellini, Alì Taher, Vip Viprakasit et al.|The Lancet Haematology|2025Cited by 17
Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS TrialValeria Santini, Matteo Della Porta, Guillermo Garcia‐Manero et al.|Blood|2024Cited by 0